Agilent Technologies, Inc. (A) Cash Flow Statement

The persistent premium of operating cash flow over net income suggests that Agilent's reported profits are backed by actual cash generation, not just accounting accruals. This is a hallmark of a mature, high-margin business with predictable cash flows from its installed base of instruments and recurring service contracts. The gap is primarily driven by depreciation and amortization, which averaged $68.3 million per quarter, and stock-based compensation, which averaged $31.9 million per quarter, both non-cash expenses that reduce net income but not operating cash flow.

The volatility in FCF margins is largely driven by the timing of working capital changes, which can swing dramatically quarter-to-quarter. For example, a $211 million working capital outflow in 2026Q2 compressed the FCF margin to 20.2%, despite solid operating cash flow. However, the trajectory from the 6.4% low in 2025Q2 to the 23.4% in 2026Q3 indicates a normalization of cash generation as the business cycle recovers. This pattern suggests that the underlying cash-generating power of the business remains intact, and the volatility is more a function of balance sheet timing than operational weakness.

The declining capital intensity suggests that Agilent is successfully leveraging its existing manufacturing and service infrastructure to support revenue growth without proportional increases in fixed asset investment. This trend is consistent with the company's strategic focus on higher-margin software and service revenues through the CrossLab segment, which require less capital expenditure than instrument manufacturing. The current CapEx/Rev ratio of 4.3% is well below the 5.8% average of the prior eight quarters, implying that the company may be in a phase of harvesting returns on prior investments.

The erratic working capital movements are typical for a company with a mix of large, lumpy capital equipment sales and a growing base of recurring service revenue. The significant outflows in 2025Q2 and 2026Q1 likely reflect inventory builds ahead of anticipated demand or the timing of collections on large instrument orders. Conversely, the inflows in 2024Q4 and 2025Q4 suggest efficient collection cycles at year-end. Investors should monitor the trend in working capital as a leading indicator of revenue recognition timing and potential future cash flow headwinds.

The company's share repurchase program has been a consistent use of cash, averaging $136 million per quarter, which supports EPS growth by reducing the share count. This is complemented by a growing dividend, which has increased from $68 million to $72 million per quarter over the period. The large $859 million acquisition in 2024Q3, likely the Resolution Bioscience deal, demonstrates management's willingness to deploy capital for strategic tuck-in acquisitions that enhance the genomics portfolio. The balance between buybacks, dividends, and M&A suggests a disciplined approach to capital deployment that prioritizes both shareholder returns and long-term growth.